If you were getting compounded tirzepatide from a telehealth pharmacy, this article is for you. The rules changed dramatically in 2025, and Compounded Tirzepatide in 2026 looks very different from even a year ago. Here is everything you need to know in plain English.
What Was Compounded Tirzepatide?
Compounded tirzepatide is a pharmacy-made version of the same active ingredient found in Mounjaro and Zepbound, manufactured by Eli Lilly. It was produced by licensed compounding pharmacies — not by Eli Lilly. From 2022 through early 2025, it was widely available at $150 to $350 per month. Millions of people used it through telehealth platforms.
Why Was It Legal?
Federal law allows pharmacies to compound versions of FDA-approved drugs when the drug is on the FDA’s official drug shortage list. Tirzepatide landed on that list in December 2022 because demand had exploded far beyond what Eli Lilly could supply. This opened the legal door for compounders under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
The Turning Point
On October 2, 2024, the FDA declared the tirzepatide shortage resolved. Eli Lilly confirmed its manufacturing capacity could meet national demand. Once a drug is off the shortage list, pharmacies can no longer legally compound it just to offer a cheaper alternative. The FDA gave pharmacies a wind-down period. State-licensed 503A pharmacies had until February 18, 2025. Outsourcing facilities under 503B had until March 19, 2025. After those dates, compounding tirzepatide for cost savings or convenience became illegal under federal law.
Is Compounded Tirzepatide in 2026 Still Legal?
Compounded Tirzepatide in 2026 is largely off-limits for most patients. State-licensed 503A pharmacies cannot compound tirzepatide except in narrow, medically documented cases — such as a verified allergy to an inactive ingredient in the brand-name product.
Cost savings alone does not qualify. Larger 503B outsourcing facilities have received FDA warning letters and face ongoing legal pressure. Some continue operating under court injunctions, but this situation is unstable and unreliable.
If a pharmacy is openly advertising cheap compounded tirzepatide in 2026, treat it as a red flag.
What Happened in Court
The compounding industry challenged the FDA in court. The Outsourcing Facilities Association filed a lawsuit in October 2024. A federal judge issued a temporary restraining order and then a preliminary injunction in late 2024, allowing some compounders to continue temporarily.
In March 2025, a federal district court in Texas denied further relief. That largely ended large-scale legal protection for compounders. Eli Lilly also filed individual lawsuits against multiple pharmacies still producing compounded tirzepatide.
Safety Risks You Should Know
Even when it was legal, compounded tirzepatide carried risks that brand-name tirzepatide does not. Compounded drugs are not FDA-approved and have not been evaluated for safety or efficacy. Quality varies between pharmacies.
Some pharmacies used salt forms of tirzepatide — such as tirzepatide sodium or acetate — which are not bioequivalent to the brand-name product. A study found that up to 40% of online pharmacies were fake or not properly licensed.
Counterfeit GLP-1 products have also been reported. The FDA has been clear that compounded drugs are not the same as FDA-approved drugs, even if they contain the same active ingredient.
Your Best Options in 2026
If you previously relied on compounded tirzepatide, here are the legitimate alternatives available now.
Through LillyDirect, you can buy Zepbound vials directly from Eli Lilly at $299 to $449 per month depending on your dose. No insurance required. You just need to refill within 45 days of each delivery to keep the discounted price.
If you have commercial insurance that covers Mounjaro or Zepbound, Eli Lilly’s savings card can bring your cost to as little as $25 per month. The card expires December 31, 2026. Medicare and Medicaid patients are excluded.
For a fully physician-supervised approach using only FDA-approved medication, TirzepatideRX Online offers once-weekly tirzepatide with home delivery, personalized treatment plans, and ongoing medical support with clear upfront pricing.
Their Monthly Plan is $399/month. Their 3-Month Bundle is $1,125 total. Their 6-Month Bundle is $2,199 total and includes nutritional guidance and premium support. You can begin your consultation here or browse the blog to learn more.
Patient Perspective
“I used compounded tirzepatide for eight months and lost 28 pounds,” shares David, 52, from California. “When the FDA changed the rules, I was nervous about switching. But my doctor moved me to Zepbound through a telehealth program. The cost was higher, but knowing I was on an FDA-approved product gave me peace of mind. And the results continued.”
Frequently Asked Questions
Is Compounded Tirzepatide in 2026 still available?
Only in narrow medically documented cases; widespread commercial compounding ended in March 2025 after the FDA declared the shortage resolved.
Is compounded tirzepatide safe?
It carries higher risks than FDA-approved tirzepatide due to lack of FDA oversight, variable manufacturing quality, and unverified salt forms used by some providers.
What happened to companies selling compounded tirzepatide?
The FDA ended enforcement discretion, issued warning letters, and Eli Lilly filed lawsuits against multiple pharmacies still producing it.
Can I still get affordable tirzepatide without compounding?
Yes — through LillyDirect vials at $299 to $449 per month, the Eli Lilly savings card at $25 per month with qualifying insurance, or transparent telehealth programs.
Will there ever be a generic tirzepatide?
Generic tirzepatide is not expected until around 2036 when Eli Lilly’s patents expire.
Final Thoughts
The world of Compounded Tirzepatide in 2026 has fundamentally changed. What was once a widely used lower-cost option is now largely illegal for most patients. The good news is that brand-name tirzepatide is more accessible than ever through Eli Lilly’s self-pay programs and physician-supervised telehealth platforms. The safest path is also now the most practical one.
References
FDA — Tirzepatide Shortage Resolved, GLP-1 Supply Statement: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
FDA Drug Label — Mounjaro Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
FDA — Compounding Under Sections 503A and 503B: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
NCPA — FDA Ends Compounding Discretion for Tirzepatide: https://ncpa.org/newsroom/qam/2025/03/13/fda-ends-compounding-discretion-tirzepatide-maintains-discretion
